Biogen Inc. (BIIB)
After hours:
Chart Events
Performance Outlook
| Previous Close | 217.30 |
| Open | 215.83 |
| Bid | 215.00 x 800 |
| Ask | 218.20 x 800 |
| Day's Range | 215.06 - 219.07 |
| 52 Week Range | 187.16 - 351.86 |
| Volume | |
| Avg. Volume | 1,069,020 |
| Market Cap | 31.664B |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | 15.53 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BIIB
Related Research
- Biogen Inc.Analyst Report: Biogen Inc.Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.RatingFair ValueEconomic Moat6 days agoMorningstar
- Yahoo Finance Video
Health care bill ‘most aggressive action’ on drug pricing: Analyst
Raymond James Healthcare Policy Analyst Chris Meekins joins Yahoo Finance Live to discuss the expectations for the Manchin-Schumer deal, expanding regulation on drug prices, out-of-pocket Medicare expenses, and the outlook for pharmaceutical company earnings.
- Motley Fool
Good News for Retirees: Lower Medicare Part B Premiums Could Be Coming
Millions of Americans are eagerly waiting to find out how much their Social Security cost-of-living adjustment (COLA) will be for 2023. One big reason why that's the case is that Social Security's COLA calculation doesn't include Medicare Part B premiums. You might wonder how Medicare Part B premiums could possibly decline.
- Barrons.com
Sarepta Will Seek Approval of Gene Therapy Before Completing Phase 3 Trial
The company had said it was in talks with the FDA about seeking early approval, but Wall Street analysts thought the agency would make it wait to apply.
